Table 1 Patient clinicopathological information.
From: ACE2 protein expression in lung tissues of severe COVID-19 infection
Characteristics | N or mean | % or range |
|---|---|---|
COVID-19 cohort (55 patients) | ||
Age | 46 y | 13–82 y |
Sex | M 38, F17 (2.2:1) | Â |
Hospitalisation time | 12.6 d | 1–88 d |
Major symptoms on admission | ||
Fever | 22 | 40.00 |
Cough | 12 | 21.82 |
Shortness of breath | 27 | 49.09 |
Major comorbidities | ||
Diabetes | 11 | 20.00 |
Cardiovascular complications | 15 | 27.27 |
Respiratory complications | 9 | 16.36 |
Cancer | 5 | 9.09 |
Liver or kidney complications | 18 | 32.73 |
Thyroid complications | 5 | 9.09 |
Aplastic anaemia | 2 | 3.64 |
Patients with no prior comorbidities | 4 | 7.27 |
Most common lung pathological features | ||
Exudative phase of diffuse alveolar damage | 25 | 45.45 |
Organizing phase of diffuse alveolar damage | 13 | 23.64 |
Acute bronchopneumonia | 5 | 9.09 |
Acute lung injury | 9 | 16.36 |
No changes | 3 | 5.45 |
Coexisting acute bronchopneumonia with DAD | 12 | Â |
Control cohort (15 subjects) | ||
Age | 43.1 y | 18–70 y |
Sex | M 8, F 7 (1:1) | Â |
Lung pathology | ||
Normal lung | 13 | 86.66 |
Diffuse alveolar haemorrhage | 1 | 6.66 |
Diffuse alveolar damage | 1 | 6.66 |
